Results 91 to 100 of about 43,155 (225)
British Journal of Pharmacology, EarlyView.Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest +3 more
wiley +1 more source
Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran +3 more
wiley +1 more source
The cross-sectional study of hepatic lipase SNPs and plasma lipid levels. [PDF]
Food Sci Nutr, 2020 Wei W +6 more
europepmc +1 more source
Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Rosa Yang +6 more
wiley +1 more source
Hepatic lipase (LIPC) sequencing in individuals with extremely high and low high-density lipoprotein cholesterol levels. [PDF]
PLoS One, 2020 Pirim D +5 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim During fasting, the liver undergoes coordinated metabolic adaptations to maintain systemic energy homeostasis. These adaptations are driven in part by glucagon, which promotes hepatic glucose production (HGP) and fatty acid oxidation (FAO) through mechanisms involving the transcription factor Foxo1.
Zheng Shen +9 more
wiley +1 more source
Equine Veterinary Education, EarlyView.Summary A 20‐year‐old Camargue pony mare was referred for acute‐onset neurological signs and intermittent colic. Clinical examination revealed obtundation, cranial nerve deficits, head pressing, ventral strabismus and ataxia. Laboratory analyses showed marked hyperammonaemia, hyperbilirubinemia, severe increases in liver enzymes, hypoalbuminaemia and ...
C. Maino +5 more
wiley +1 more source